Steven Pascoe

4.1k citations

49 papers · 2.7k indexed · 2 hit papers · h-index 17

Impact in

Physiology top 1%
- Asthma and respiratory diseases
Pulmonary and Respiratory Medicine top 0.5%
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory Support and Mechanisms
- Respiratory and Cough-Related Research
- Inhalation and Respiratory Drug Delivery
- Neonatal Respiratory Health Research

Papers in ⓘ

Physiology 38
- Asthma and respiratory diseases 38
Pulmonary and Respiratory Medicine 43
- Chronic Obstructive Pulmonary Disease (COPD) Research 31
- Respiratory and Cough-Related Research 16
- Inhalation and Respiratory Drug Delivery 13
- Respiratory Support and Mechanisms 11
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 1

Co-authors: Mark T. Dransfield (9 shared papers)Neil Barnes (14 shared papers)Ian Pavord (11 shared papers)Nicholas Locantore (4 shared papers)David A. Lipson (10 shared papers)David A. Lomas (8 shared papers)Maggie Tabberer (5 shared papers)Noushin Brealey (3 shared papers)
Journals: Respiratory Medicine (7 papers)International Journal of COPD (3 papers)The Lancet Respiratory Medicine (3 papers)Respiratory Research (3 papers)New England Journal of Medicine (3 papers)
Partner nations: United Kingdom United States Denmark

In The Last Decade

Steven Pascoe

47 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD 2018 · 758 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 New England Journal of Medicine
2015 The Lancet Respiratory Medicine

Peers

Countries citing papers authored by Steven Pascoe

Since Specialization

Citations

This map shows the geographic impact of Steven Pascoe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Pascoe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Pascoe more than expected).

Fields of papers citing papers by Steven Pascoe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Pascoe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Pascoe. The network helps show where Steven Pascoe may publish in the future.

Co-authors

The 25 scholars most cited alongside Steven Pascoe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Steven Pascoe Line = papers co-authored together Steven Pascoe links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD New England Journal of Medicine ·David A. Lipson, Frank Barnhart, Noushin Brealey, Jean Brooks, Gerard J. Criner, Nicola C. Day, Mark T. Dransfield, David Halpin, MeiLan K. Han, Christine Jones, Sally Kilbride, Peter Lange, David A. Lomas, Fernando J. Martínez, Dave Singh, Maggie Tabberer, Robert A. Wise, Steven Pascoe Hit paper breakdown →	2018	758
2	Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials The Lancet Respiratory Medicine ·Steven Pascoe, Nicholas Locantore, Mark T. Dransfield, Neil Barnes, Ian Pavord Hit paper breakdown →	2015	504
3	FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease American Journal of Respiratory and Critical Care Medicine ·David A. Lipson, Helen Barnacle, Ruby Birk, Noushin Brealey, Nicholas Locantore, David A. Lomas, Andrea Ludwig-Sengpiel, Rajat Mohindra, Maggie Tabberer, Chang‐Qing Zhu, Steven Pascoe	2017	226
4	Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial The Lancet Respiratory Medicine ·Steven Pascoe, Neil Barnes, Guy Brusselle, Chris Compton, Gerard J. Criner, Mark T. Dransfield, David Halpin, MeiLan K. Han, Benjamin Hartley, Peter Lange, Sally Lettis, David A. Lipson, David A. Lomas, Fernando J. Martínez, Alberto Papi, Nicolás Roche, Ralf J.P. van der Valk, Robert A. Wise, Dave Singh	2019	153
5	Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial The Lancet Respiratory Medicine ·Laurie A. Lee, Zelie Bailes, Neil Barnes, Louis‐Philippe Boulet, Dawn Edwards, Andrew Fowler, Nicola A. Hanania, Huib A.M. Kerstjens, Edward Kerwin, Robert A. Nathan, John Oppenheimer, Alberto Papi, Steven Pascoe, Guy Brusselle, Guy Peachey, Neal Sule, Maggie Tabberer, Ian Pavord	2020	150
6	Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease American Journal of Respiratory and Critical Care Medicine ·David A. Lipson, Courtney Crim, Gerard J. Criner, Nicola C. Day, Mark T. Dransfield, David Halpin, MeiLan K. Han, Christine Jones, Sally Kilbride, Peter Lange, David A. Lomas, Sally Lettis, P Manchester, Neil Martin, Dawn Midwinter, Andrea Morris, Steven Pascoe, Dave Singh, Robert A. Wise, Fernando J. Martínez	2020	146
7	Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone New England Journal of Medicine ·David A. Stempel, Ibrahim Raphiou, Kenneth M. Kral, Anne Yeakey, Amanda Emmett, Charlene M. Prazma, Kathleen S. Buaron, Steven Pascoe	2016	104
8	Blood eosinophil levels as a biomarker in COPD Respiratory Medicine ·Guy Brusselle, Ian Pavord, Sarah Landis, Steven Pascoe, Sally Lettis, Nikhil Morjaria, Neil Barnes, Emma Hilton	2018	86
9	Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma New England Journal of Medicine ·David A. Stempel, Stanley J. Szefler, Søren Pedersen, Robert S. Zeiger, Anne Yeakey, Laurie A. Lee, Andrew H. Liu, Herman Mitchell, Kenneth M. Kral, Ibrahim Raphiou, Barbara A. Prillaman, Kathleen S. Buaron, Suyong Yun Kirby, Steven Pascoe	2016	77
10	Understanding asthma-chronic obstructive pulmonary disease overlap syndrome Respiratory Medicine ·Keele Wurst, Kaitlin Kelly‐Reif, Greta Bushnell, Steven Pascoe, Neil Barnes	2015	72
11	A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol European Respiratory Journal ·Steven Pascoe, David A. Lipson, Nicholas Locantore, Helen Barnacle, Noushin Brealey, Rajat Mohindra, Mark T. Dransfield, Ian Pavord, Neil Barnes	2016	60
12	The effect of fluticasone furoate/umeclidinium in adult patients with asthma: A randomized, dose-ranging study Respiratory Medicine ·Laurie A. Lee, Shuying Yang, Edward Kerwin, Roopa Trivedi, Lisa Edwards, Steven Pascoe	2014	45
13	Bronchodilator effects of indacaterol and formoterol in patients with COPD Pulmonary Pharmacology & Therapeutics ·Jutta Beier, Kai Michael Beeh, L Brookman, Guy Peachey, Abdel Hmissi, Steven Pascoe	2009	36
14	A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma Respiratory Medicine ·Laurie A. Lee, Anne Briggs, Lisa Edwards, Shuying Yang, Steven Pascoe	2014	35
15	Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis BMJ Open ·David Hinds, Rachael L. DiSantostefano, Hoa Le, Steven Pascoe	2016	33
16	Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids International Journal of COPD ·Salman Siddiqui, Ian Pavord, Neil Barnes, Alessandro Guasconi, Sally Lettis, Steven Pascoe, Stefano Petruzzelli	2018	23
17	A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ≤2% and >2% blood eosinophils Respiratory Medicine ·Joanna Marks-Kończalik, María J. Costa, Jon Robertson, Elizabeth McKie, Shuying Yang, Steven Pascoe	2015	19
18	Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD Respiratory Medicine ·Steven Pascoe, María J. Costa, Joanna Marks-Kończalik, Elizabeth McKie, Shuying Yang, Pablo Sáez Scherbovsky	2017	15
19	Seasonal variation in asthma exacerbations in the AUSTRI and VESTRI studies ERJ Open Research ·Stanley J. Szefler, Ibrahim Raphiou, Robert S. Zeiger, David A. Stempel, Kenneth M. Kral, Steven Pascoe	2019	13
20	The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study Respiratory Medicine ·Laurie Lee, Edward Kerwin, Kathryn Collison, Linda Nelsen, Wei Wu, Shuying Yang, Steven Pascoe	2017	10

About Steven Pascoe

Steven Pascoe is a scholar working on Physiology, Pulmonary and Respiratory Medicine, Biological Psychiatry, Genetics and Hematology, having authored 49 papers that have together received 2.7k indexed citations. Recurring topics across this work include Asthma and respiratory diseases (38 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (31 papers), Respiratory and Cough-Related Research (16 papers), Inhalation and Respiratory Drug Delivery (13 papers), Respiratory Support and Mechanisms (11 papers), Delphi Technique in Research (2 papers), Eosinophilic Disorders and Syndromes (2 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (1 paper). The work is most often cited by research in Physiology (2.1k citations), Pulmonary and Respiratory Medicine (2.5k citations), Issues, ethics and legal aspects (49 citations), Emergency Medical Services (186 citations) and Immunology and Allergy (42 citations). Steven Pascoe has collaborated with scholars based in United Kingdom, United States and Denmark. Frequent co-authors include Mark T. Dransfield, Neil Barnes, Ian Pavord, Nicholas Locantore, David A. Lipson, David A. Lomas, Maggie Tabberer, Noushin Brealey, Dave Singh and Robert A. Wise. Their work appears in journals such as Respiratory Medicine, International Journal of COPD, The Lancet Respiratory Medicine, Respiratory Research and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact